検索
Cingulate Inc
CINGウォッチリストに追加
4.570USD
+0.180+4.10%
終値 05/15, 16:00（ET）15分遅れの株価
60.67M時価総額
損失額直近12ヶ月PER
詳細情報 Cingulate Inc 企業名
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Cingulate Incの企業情報
企業コードCING
会社名Cingulate Inc
上場日Oct 07, 2021
最高経営責任者「CEO」Callahan (Jennifer L)
従業員数13
証券種類Ordinary Share
決算期末Oct 07
本社所在地1901 W. 47Th Place
都市KANSAS CITY
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号66205
電話番号19139422300
ウェブサイトhttps://www.cingulate.com/
企業コードCING
上場日Oct 07, 2021
最高経営責任者「CEO」Callahan (Jennifer L)
Cingulate Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Dr. Matthew N. (Matt) Brams, M.D.
Dr. Matthew N. (Matt) Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Nilay Patel, J.D.
Mr. Nilay Patel, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Dr. Matthew N. (Matt) Brams, M.D.
Dr. Matthew N. (Matt) Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Thu, May 14
更新時刻: Thu, May 14
株主統計
種類
株主統計
株主統計
比率
Falcon Creek Capital Advisor LLC
31.48%
Vanguard Capital Management, LLC
2.52%
Kestra Advisory Services, LLC
1.14%
Werth Family Investment Associates LLC
0.96%
Hargroves (Thomas Jeffrey)
0.80%
他の
63.10%
株主統計
株主統計
比率
Falcon Creek Capital Advisor LLC
31.48%
Vanguard Capital Management, LLC
2.52%
Kestra Advisory Services, LLC
1.14%
Werth Family Investment Associates LLC
0.96%
Hargroves (Thomas Jeffrey)
0.80%
他の
63.10%
種類
株主統計
比率
Corporation
32.52%
Investment Advisor
5.77%
Individual Investor
1.08%
Investment Advisor/Hedge Fund
0.57%
Venture Capital
0.17%
Hedge Fund
0.13%
Research Firm
0.06%
他の
59.71%
機関投資家保有株
更新時刻: Wed, Apr 1
更新時刻: Wed, Apr 1
報告期間
機関投資家数
保有株式数
比率
変動額
2026Q1
38
556.12K
4.54%
-23.76K
2025Q4
33
295.34K
5.70%
--
2025Q3
44
295.34K
6.89%
+113.00
2025Q2
41
295.23K
5.36%
+158.62K
2025Q1
38
136.60K
4.92%
-48.84K
2024Q4
38
91.23K
3.95%
+40.70K
2024Q3
38
50.54K
3.01%
-30.23K
2024Q2
36
80.24K
1.97%
+46.92K
2024Q1
36
33.32K
1.85%
+25.60K
2023Q4
33
318.00
10.05%
-5.36K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Falcon Creek Capital Advisor LLC
3.86M
33.26%
+1.78M
+85.96%
Mar 24, 2026
Kestra Advisory Services, LLC
122.00K
1.05%
+27.98K
+29.76%
Dec 31, 2025
Werth Family Investment Associates LLC
117.45K
1.01%
+19.45K
+19.85%
Feb 13, 2026
Hargroves (Thomas Jeffrey)
97.47K
0.84%
+97.47K
--
Feb 13, 2026
Geode Capital Management, L.L.C.
61.03K
0.53%
+18.63K
+43.93%
Dec 31, 2025
DRW Securities, LLC
58.67K
0.51%
+58.67K
--
Dec 31, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
日付
配当落ち日
種類
比率
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
